Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Free Report) Director Marcelo Bigal bought 1,512 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were purchased at an average price of $13.25 per share, for a total transaction of $20,034.00. Following the completion of the purchase, the director now directly owns 10,142 shares of the company’s stock, valued at approximately $134,381.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Pacira BioSciences Price Performance
Shares of NASDAQ:PCRX opened at $13.89 on Wednesday. Pacira BioSciences, Inc. has a one year low of $11.16 and a one year high of $38.23. The stock has a market capitalization of $646.52 million, a price-to-earnings ratio of 9.71 and a beta of 0.88. The company has a 50-day simple moving average of $21.68 and a 200-day simple moving average of $26.42. The company has a debt-to-equity ratio of 0.67, a quick ratio of 5.70 and a current ratio of 6.82.
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.53 by $0.11. Pacira BioSciences had a return on equity of 13.22% and a net margin of 9.21%. The firm had revenue of $178.02 million during the quarter, compared to the consensus estimate of $173.31 million. On average, analysts predict that Pacira BioSciences, Inc. will post 2.22 EPS for the current year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Pacira BioSciences
Institutional Investors Weigh In On Pacira BioSciences
Several large investors have recently modified their holdings of PCRX. ICA Group Wealth Management LLC acquired a new position in Pacira BioSciences in the 4th quarter valued at $30,000. GAMMA Investing LLC boosted its holdings in shares of Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after acquiring an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new stake in shares of Pacira BioSciences in the second quarter valued at about $46,000. Innealta Capital LLC acquired a new position in shares of Pacira BioSciences during the second quarter worth about $50,000. Finally, nVerses Capital LLC raised its holdings in Pacira BioSciences by 800.0% during the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.
About Pacira BioSciences
Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
Recommended Stories
- Five stocks we like better than Pacira BioSciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- Consumer Discretionary Stocks Explained
- Lowe’s Stock: Hold Now, Buy it When it Dips
- The Most Important Warren Buffett Stock for Investors: His Own
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.